TestAMLtable

From Compendium of Cancer Genome Aberrations
Revision as of 13:44, 8 October 2018 by Pitel.Beth (talk | contribs) (Created page with "{| class="wikitable" |- ! Chromosome ! AML subtype ! Abnormality type (gain, loss, CN-LOH) ! Region ! Relevant genes (if known) ! Clinical significance ! Level of Evidence ! R...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Chromosome AML subtype Abnormality type (gain, loss, CN-LOH) Region Relevant genes (if known) Clinical significance Level of Evidence Reference
1 AML including NK-AML CN-LOH 1p D 3 [11, 29, 30, 67-69, 102-104]
2 AML CN-LOH 2p DNMT3A D 3 [11, 65, 100]
3 NK-AML, sAML Loss 3p14.1 FOXP1 D 3 [30, 57, 66]
4 sAML, pAML CN-LOH 4q24 TET2 D 3 [67, 71, 105]
4 AML, NK-AML, sAML Loss 4q24 TET2 D, P 3 [42, 45, 66]
5 pAML, sAML Loss 5q D 1 [24, 33, 45, 49, 57, 66, 77, 87, 88, 106-108]
6 AML including NK-AML CN-LOH 6p D 3 [29, 30, 102, 104]
7 AML including NK-AML CN-LOH 7q EZH2 D 3 [67, 102, 109]
7 NK-AML, pAML, sAML Loss 7q EZH2, CUX1 D 1 [28, 57, 66, 110]
8 complex karyotype AML Amplification 8q24 MYC D, P 3 [24, 49, 61]
9 NK-AML, sAML CN-LOH 9p JAK2 D 3 [66, 67, 104]
11* AML w complex karyotype Amplification 11q23 MLL (KMT2A) D, P 3 [49, 111]
11* AML CN-LOH 11p WT1 D 3 [11, 30, 65, 102]
11 pAML, sAML, NK-AML CN-LOH 11q CBL D 3 [11, 65-67, 102]
12 AML, NK-AML, AML w complex karyotype, sAML Loss 12p13.2 ETV6 D 3 [24, 30, 33, 49, 57, 61, 66, 77, 104, 108, 111-115]
13* pAML, NK-AML, NPM1 mutated AML, FLT3-ITD pos AML, sAML CN-LOH 13q FLT3 D, P 2 [11, 28-31, 65-69, 102, 104, 109, 116-118]
16 NK-AML, AML w complex karyotype, pAML, sAML Loss 16q CBFB D 3 [29, 49, 61, 108]
17 AML, NK-AML, pAML, sAML CN-LOH 17p TP53 D 3 [11, 28, 29, 65, 67, 102, 107]
17 sAML, NK-AML, AML w complex karyotype, de novo AML Loss 17p TP53 D, P 1 [24, 28, 29, 49, 61, 66, 88, 106-108, 114]
17 NK-AML, pAML Loss 17q11.2 NF1, SUZ12 D, P 3 [24, 28, 29, 47-49, 61, 66, 104, 111]
19* AML, NK-AML, sAML CN-LOH 19q CEBPA D 3 [11, 29, 30, 69, 102, 105]
20 sAML Loss 20q D 3 [24, 66, 119, 120]
21* pAML, AML w complex karyotype Amplification 21q22 ERG, ETS2 D, P, T 3 [49, 57, 61, 62, 121]
21* AML, NK-AML, sAML CN-LOH 21q RUNX1 D 3 [11, 29, 67, 70, 102-105]
21* sAML Loss 21q22.12 RUNX1 D 3 [57]